Serum Institute to launch Sputnik V production

14:41, 13 July 2021
Serum Institute to launch Sputnik V production Photo: REUTERS

The world's largest manufacturer of vaccines is negotiating with Moscow to start producing the Russian vaccine. 

India's Serum Institute and the Russian Direct Investment Fund (RDIF) have revealed plans of cooperation. 

RDIF, which is the main developer and promoter of Sputnik V internationally, wants India to produce approximately 300 mln doses of the vaccine each year. 

After the signing of the contract, the start of production is scheduled for September. 

RDIF adds that the cell and vector samples of the vaccine have already been sent to Serum Institute. 

SII is the 7th partner of Russia to produce Sputnik V in India. 

Kirill Dmitriev, RDIF’s CEO, has already expressed satisfaction with the result, highlighting that the cooperation will save many lives not only in India but around the world. 

Sputnik V has been registered in 67 countries overall, including Argentina, Serbia, Hungary, Mexico, and UAE, with a total population of over 3.5 bln people.